Menu
Back to User profile » Dr Danielle Brazel
Papers published by Dr Danielle Brazel:
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:63-69
Published Date: 23 June 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Brazel D, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:1-9
Published Date: 5 January 2023
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Brazel D, Arter Z, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:75-80
Published Date: 10 November 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:47-52
Published Date: 19 May 2022
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Brazel D, Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:33-45
Published Date: 13 May 2022
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:133-138
Published Date: 2 December 2021